Investors on the quest for market-beating returns often employ the strategy of stock picking. Making informed choices in stocks can greatly amplify your wealth.
The closing price of Collegium Pharmaceutical Inc (NASDAQ: COLL) was $46.9 for the day, up 0.71% from the previous closing price of $46.57. In other words, the price has increased by $0.71 from its previous closing price. On the day, 0.72 million shares were traded. COLL stock price reached its highest trading level at $47.105 during the session, while it also had its lowest trading level at $45.81.
Ratios:
Our analysis of COLL’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.85 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 5.12. For the most recent quarter (mrq), Quick Ratio is recorded 1.27 and its Current Ratio is at 1.36. In the meantime, Its Debt-to-Equity ratio is 3.41 whereas as Long-Term Debt/Eq ratio is at 3.17.
Upgrades & Downgrades
In the most recent recommendation for this company, Barclays on December 09, 2025, initiated with a Overweight rating and assigned the stock a target price of $58.
On January 10, 2025, Needham Upgraded its rating to Buy which previously was Hold but kept the price unchanged to $46.
H.C. Wainwright Upgraded its Neutral to Buy on July 30, 2024, while the target price for the stock was maintained at $47.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 05 ’25 when RITA BALICE-GORDON bought 3,650 shares for $47.03 per share.
Dreyer Scott sold 17,600 shares of COLL for $847,855 on Dec 08 ’25. The EVP & Chief Commercial Officer now owns 103,613 shares after completing the transaction at $48.17 per share. On Dec 05 ’25, another insider, Balice-Gordon Rita J., who serves as the Director of the company, sold 3,650 shares for $47.03 each. As a result, the insider received 171,673 and left with 52,629 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, COLL now has a Market Capitalization of 1482554880 and an Enterprise Value of 2132959744. As of this moment, Collegium’s Price-to-Earnings (P/E) ratio for their current fiscal year is 29.19, and their Forward P/E ratio for the next fiscal year is 5.44. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 1.34. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.96 while its Price-to-Book (P/B) ratio in mrq is 5.39. Its current Enterprise Value per Revenue stands at 2.817 whereas that against EBITDA is 5.317.
Stock Price History:
The Beta on a monthly basis for COLL is 0.64, which has changed by 0.39640176 over the last 52 weeks, in comparison to a change of 0.15507638 over the same period for the S&P500. Over the past 52 weeks, COLL has reached a high of $50.79, while it has fallen to a 52-week low of $23.23. The 50-Day Moving Average of the stock is 0.99%, while the 200-Day Moving Average is calculated to be 31.40%.
Shares Statistics:
COLL traded an average of 507.51K shares per day over the past three months and 489830 shares per day over the past ten days. A total of 31.60M shares are outstanding, with a floating share count of 30.56M. Insiders hold about 3.32% of the company’s shares, while institutions hold 120.06% stake in the company. Shares short for COLL as of 1767139200 were 5415274 with a Short Ratio of 10.67, compared to 1764288000 on 5878047. Therefore, it implies a Short% of Shares Outstanding of 5415274 and a Short% of Float of 20.51.
Earnings Estimates
As of right now, 5.0 analysts gave their recommendation on the stock of the company. The consensus estimate for the next quarter is $1.62, with high estimates of $1.85 and low estimates of $1.47.
Analysts are recommending an EPS of between $7.6 and $7.24 for the fiscal current year, implying an average EPS of $7.47. EPS for the following year is $7.94, with 5.0 analysts recommending between $10.08 and $7.03.
Revenue Estimates
It is expected that $90B in revenue will be generated in. The current quarter, according to 5 analysts. It ranges from a high estimate of $209.7M to a low estimate of $204.2M. As of. The current estimate, Collegium Pharmaceutical Inc’s year-ago sales were $181.95MFor the next quarter, 5 analysts are estimating revenue of $194.75M. There is a high estimate of $202.7M for the next quarter, whereas the lowest estimate is $188M.
A total of 5 analysts have provided revenue estimates for COLL’s current fiscal year. The highest revenue estimate was $784.8M, while the lowest revenue estimate was $779.4M, resulting in an average revenue estimate of $781.29M. In the same quarter a year ago, actual revenue was $631.45MBased on 5 analysts’ estimates, the company’s revenue will be $808.06M in the next fiscal year. The high estimate is $827M and the low estimate is $777.3M.
